NEW YORK (GenomeWeb News) – The National Institute of Mental Health’s Laboratory of Neurotoxicology is seeking interested parties to collaborate in a research alliance to develop and commercialize protein quantification techniques using mass spectrometry.
NIMH said the technology can be used in basic research, to diagnose disease, or determine amounts of specific marker proteins in heterogeneous mixtures such as blood or urine.
The technology, which uses a combination of recombinant DNA technology, fluorescence, proteolytic, and mass spectrometric methods, is currently in the pre-clinical validation phase.
Some applications of the technology could include cell signaling, cell cycle function, developing calibration standards for mass spectrometry and non-mass-spectrometric techniques, and in determining post-translation modification of a signature peptide.
Investigators interested in finding out more information may view the NIMH announcement here.